Cidara Therapeutics Inc banner

Cidara Therapeutics Inc
NASDAQ:CDTX

Watchlist Manager
Cidara Therapeutics Inc Logo
Cidara Therapeutics Inc
NASDAQ:CDTX
Watchlist
Price: 221.38 USD Market Closed
Market Cap: $7B

Multiples-Based Value

The Multiples-Based Value of one CDTX stock under the Base Case scenario is hidden USD. Compared to the current market price of 221.38 USD, Cidara Therapeutics Inc is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CDTX Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

CDTX Competitors Multiples
Cidara Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Cidara Therapeutics Inc
NASDAQ:CDTX
6.5B USD 0 -35.2 -40.4 -40.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
366.3B USD 6 87.5 14.5 20.2
US
Exact Sciences Corp
NASDAQ:EXAS
355.9B USD 109.6 -1 710.6 15 890.6 -1 794.3
US
Amgen Inc
NASDAQ:AMGN
190.8B USD 5.2 24.7 14.3 14.3
US
Gilead Sciences Inc
NASDAQ:GILD
171.6B USD 5.8 20.2 12.6 15.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD 9.6 29.2 22 23
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD 5.5 17.6 13 14.9
AU
CSL Ltd
ASX:CSL
68B AUD 3.2 35.2 11.6 14.6
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
US
Cidara Therapeutics Inc
NASDAQ:CDTX
Average P/S: 3 369 312.9
Not Available
100%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6
9%
0.7
US
Exact Sciences Corp
NASDAQ:EXAS
109.6
12%
9.1
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
5.8
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.6
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Cidara Therapeutics Inc
NASDAQ:CDTX
Average P/E: 35.7
Negative Multiple: -35.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.5
97%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -1 710.6 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.7
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.2
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
29.2
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
13%
1.4
AU
CSL Ltd
ASX:CSL
35.2
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Cidara Therapeutics Inc
NASDAQ:CDTX
Average EV/EBITDA: 2 282.7
Negative Multiple: -40.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.5
12%
1.2
US
Exact Sciences Corp
NASDAQ:EXAS
15 890.6
261%
60.9
US
Amgen Inc
NASDAQ:AMGN
14.3
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.6
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13
18%
0.7
AU
CSL Ltd
ASX:CSL
11.6
7%
1.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Cidara Therapeutics Inc
NASDAQ:CDTX
Average EV/EBIT: 17.1
Negative Multiple: -40.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.2
23%
0.9
US
Exact Sciences Corp
NASDAQ:EXAS
Negative Multiple: -1 794.3 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
14.3
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
15.6
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.9
23%
0.6
AU
CSL Ltd
ASX:CSL
14.6
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett